How a narrow FDA label could smooth rezafungin’s launch

Cidara Therapeutics is betting that when it comes to commercializing antimicrobials, less can be more. An FDA advisory committee’s endorsement of the company’s antifungal rezafungin for a limited population could help overcome hospitals’ fears that it will be a budget-buster.

FDA’s Antimicrobial Drugs Advisory Committee (ADAC) recommended approval of rezafungin on Jan. 24, voting 14-1 that the antifungal’s overall benefit-risk assessment was favorable to treat candidemia/invasive candidiasis in adults with limited or no alternative treatment options. ...